Anastrozol
Anastrozol is a non-steroidal aromatase inhibitor used in the treatment of estrogen receptor-positive breast cancer, primarily in postmenopausal women. It is marketed under the brand name Arimidex and as a generic medication. By inhibiting the aromatase enzyme (CYP19) in peripheral tissues, it lowers estrogen production and reduces the growth stimulus for ER-positive tumors.
Anastrozol is indicated as adjuvant therapy for postmenopausal women with early-stage ER-positive breast cancer to reduce
The usual dose is 1 mg taken orally once daily, with or without food. In adjuvant therapy,
Common adverse effects include hot flashes, joint or muscle pain (arthralgia/myalgia), fatigue, nausea, and decreased bone
Contraindications include pregnancy and breastfeeding. In premenopausal women, anastrozol is generally ineffective unless ovarian function is
Pharmacokinetically, anastrozol is well absorbed orally and has a half-life of about 40–50 hours, with hepatic